ADVM — Adverum Biotechnologies Share News
0.000.00%
Last trade - 00:00- $94.05m
- $67.99m
- $1.00m
Brief: Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD
Brief: Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule
Adverum Biotechnologies Inc expected to post a loss of $1.31 a share - Earnings Preview
Brief: Adverum Biotechnologies Appoints Jason L. Mitchell As Chief Commercial Officer As It Prepares To Initiate Pivotal Program
U.S. RESEARCH ROUNDUP-Agenus, Guardant Health, Zoetis
U.S. RESEARCH ROUNDUP- Apollo, Blackstone, Hershey
Adverum Biotechnologies Inc expected to post a loss of $1.47 a share - Earnings Preview
Adverum Biotechnologies Inc reports results for the quarter ended in March - Earnings Summary
Adverum Biotechnologies Inc expected to post a loss of $1.40 a share - Earnings Preview
Brief: Adverum Biotechnologies Files For Mixed Shelf Offering Of $200 Million
U.S. RESEARCH ROUNDUP-American Tower, Lennar, Nike
Brief: Adverum Biotechnologies Announces $127.5 Million Private Placement Financing
Brief: Adverum Biotechnologies Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Adverum Biotechnologies Appoints C David Nicholson to its Board
U.S. RESEARCH ROUNDUP-Arthur J. Gallagher & Co., Costco Wholesale, Idexx Laboratories
Brief: Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data From The Luna Phase 2 Trial
Adverum Biotechnologies Inc reports results for the quarter ended in June - Earnings Summary
Brief: Adverum Biotechnologies Completes Enrollment Of Phase 2 Luna Trial In Wet AMD